<DOC>
	<DOC>NCT00457808</DOC>
	<brief_summary>The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.</brief_summary>
	<brief_title>Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM</brief_title>
	<detailed_description>The study design was an open label, phase I/II trial of sirolimus for one year followed by one year off therapy.Patients were seen at baseline,at two weeks to four weeks, and at 2,4,6,9,12,18 and 24 months. Angiomyolipomata imaging was performed at all but the two to four week visit. Complete pulmonary function tests and six-minute walk were obtained at baseline,6 or 9 month, 12 and 24 month visits, while simple spirometry only was performed at all other visits.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Diagnosed with angiomyolipomas and have either Tuberous Sclerosis complex or Lymphangioleiomyomatosis Between the gaes of 18 and 65 years Competency to voluntarily consent Clinically definite diagnosis of tuberous sclerosis or SLAM Adequate contraception At least one angiomyolipoma of 1 cm or greater in largest diameter Use of continuous supplemental oxygen Concurrent infection Recent surgery Ongoing or planned pregnancy Lactation Use of an investigational drug within the last 30 days of study entrance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>TSC and LAM</keyword>
	<keyword>Tuberous Sclerosis Complex and sporadic LAM</keyword>
</DOC>